read theCongregationLog.

Most AI initiatives in private equity portfolios never translate into EBITDA uplift. This article explains why value gets lost, how ROI fog forms, and what operating partners consistently underestimate.

Private equity has poured billions into MSP roll-ups over the last decade. The thesis is familiar: acquire strong regional operators, standardise operations, unlock scale, and expand margins. On paper, it works. In reality, most MSP platforms hit an invisible wall somewhere between acquisition #2 and #4.

Across private equity portfolios, the same conversation repeats itself. An AI pilot shows promise. A proof of concept is funded. Early results look encouraging. Then time passes.

Corporate leaders love strategy. Roadmaps. Frameworks. Vision decks. It all looks impressive — until you ask the obvious question: "what have we actually built?"

In modern marketing, the greatest threat to momentum isn’t competition — it’s overthinking. Teams spend months perfecting roadmaps and revising slides, paralysed by the pursuit of “the perfect plan.”

Corporate leaders love certainty. They want iron-clad business cases, five-year forecasts, and endless slide decks before they spend a penny. It feels safe. It looks rigorous. But here’s the brutal truth: **endless planning is the fastest way to waste money.**

SMEs don’t struggle because of lack of ambition — they struggle because manual work and outdated systems drain time. Learn how AI systems remove the drag and unlock faster, more sustainable growth.

Let’s start with a quiet truth most SME leaders admit only to themselves: You *know* your business has valuable data… you just don’t have the time, tools or people to make sense of it.

Epidemiology has always been the science of patterns — tracking how diseases spread, who they affect, and what can be done to stop them. From John Snow mapping cholera in 19th-century London to modern flu surveillance systems, epidemiologists have shaped public health for centuries.